 SAN DIEGO, Feb. 18, 2021 GLOBE NEWSWIRE -- TRACON Pharmaceuticals NASDAQ:TCON, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that it will report its fourth quarter and full year 2020 financial and operating results after the close of U.S. financial markets on Thursday, February 25, 2021. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results. 